Related Experiment Video

Updated: Jun 4, 2026

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
13:45

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Published on: December 23, 2010

Genetic contribution of the leukotriene pathway to coronary artery disease

Jaana Hartiala1, Dalin Li, David V Conti

  • 1Department of Preventive Medicine, USC Keck School of Medicine, Los Angeles, CA 90033, USA.

Human Genetics
|February 5, 2011
PubMed

Insights

Genetic variations in the leukotriene (LT) pathway influence coronary artery disease (CAD) risk. Specific ALOX5 and LTA4H variants increase CAD risk, while a PLA2G4A variant offers protection.

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Immunology

Background:

  • The leukotriene (LT) pathway plays a role in inflammation and immune responses.
  • Genetic factors contributing to coronary artery disease (CAD) risk are actively investigated.
  • Understanding the genetic contribution of the LT pathway to CAD is crucial for risk stratification and potential therapeutic targets.

Purpose of the Study:

  • To evaluate the genetic contribution of leukotriene pathway variants to coronary artery disease (CAD) risk.
  • To identify specific genetic variants within the LT pathway associated with CAD in different ethnic groups.
  • To explore the functional consequences of identified genetic variants on leukotriene production and their association with major adverse cardiac events.

Main Methods:

  • Genomic association studies in a cohort of 4,512 Caucasian and African American subjects.
  • Analysis of promoter repeat polymorphisms in ALOX5 and LTA4H haplotypes.
  • Genome-wide SNP analysis and targeted follow-up of LT pathway genes.
  • Functional experiments assessing leukotriene B4 (LTB4) production in monocytes.

Main Results:

  • Shorter alleles of ALOX5 increased CAD risk in African Americans (OR=1.4).
  • LTA4H haplotype (HapK) and SNP (rs2540477) were associated with increased CAD risk in Caucasians (OR=1.2).
  • PLA2G4A SNP (rs12746200) decreased CAD risk (OR=0.7) and major adverse cardiac events (MACE) risk (HR=0.7).
  • Carriers of LTA4H variants showed significantly higher LTB4 production.

Conclusions:

  • Functional genetic variations in the leukotriene pathway contribute to atherogenic processes and CAD risk.
  • Specific LT pathway genes, including LTA4H and PLA2G4A, represent potential targets for understanding and managing CAD.
  • LTB4 production is linked to genetic variants and may play a direct role in monocyte recruitment in atherosclerosis.

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...